Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
The partnership between 3Z and biotx.ai aims to establish a robust bridge from animal discovery studies to human clinical trials. By utilizing comprehensive AI-powered human genetics-based modelling, the involvement of the lead therapeutic targets in ADHD will be thoroughly explored.
AGLE-102 is an investigational product comprised of native extracellular vesicles isolated from allogeneic stem cells using Aegle's proprietary and patented methods. The product is a composite of cell-derived nanoparticles that contain active biomolecules including proteins and nucleic acids with tissue regeneration, immunomodulation, and anti-inflammation properties.
"I have been involved in the study of polidocanol for vein sclerotherapy for more than 40 years and am proud to lead the scientific and clinical effort to study this novel formulation of it for a new indication," said Mitchel P. Goldman, M.D., a dermatologic surgeon and medical director of Platinum and West Dermatology. "I believe that 10XB101 can achieve superior efficacy and tolerability than the currently marketed body contouring drug, deoxycholate, which I have more than 10 years of experience with. I look forward to seeing the results of this trial."
“NDA Group is regarded as the premier regulatory consultancy for Life Sciences companies across the U.S. and Europe, and we’re delighted to build upon our longstanding partnership with this combination,” said Doug Locke, Chief Executive Officer of SSI Strategy.
Polycythemia vera (PV) is a cancer originating from a disease-initiating stem cell in the bone marrow resulting in a chronic increase of red blood cells, white blood cells, and platelets. PV may result in cardiovascular complications such as thrombosis and embolism, and often transforms to secondary myelofibrosis or leukemia. While the molecular mechanism underlying PV is still subject of intense research, current results point to a set of acquired mutations, the most important being a mutant form of JAK2
First and only AFib ablation products to receive approval for use in a workflow without fluoroscopy from the U.S. Food and Drug Administration. Enables workflows with zero fluoroscopy during catheter ablation procedures. The approval is based on data from REAL AF Registry, demonstrating value of real-world evidence
“Our technology’s capability to monitor a patient's function in office and then at the patient’s home over a period of time is a catalyst for change in healthcare – signifying cost savings for patients and payers,” says Carter Brown, CEO, BioMech Health. “Because BioMech Lab can set baselines in the office and then monitor a patient’s progress at home, physicians can actively ascertain patient progress without having to incur the inconvenience and costs of an office visit.”
Dr Andrew Southan, Chief Executive of Metrion Biosciences, said: “The launch of our GLP hERG screening capability adds further depth to our ion channel drug discovery services and complements our existing cardiac safety service portfolio. Our team is pleased to be able to offer GLP quality services to new and existing clients globally as we continue to develop Metrion as a leading ion channel focused CRO.”
BRIUMVI is the first and only anti-CD20 monoclonal antibody approved in the United States (US) and European Union (EU) for adult patients with relapsing forms of multiple sclerosis (RMS) that can be administered in a one-hour infusion, twice a year, following the starting dose. Neuraxpharm is backed by funds advised by the global private equity firm, Permira.
By using this website you agree to accept Medical Device News Magazine Privacy Policy
